drugset / Trial / NCT03727295
Idebenone Treatment of Early Parkinson's Diseasesymptoms
Phase 4
Unknown
180 enrolled
Second Affiliated Hospital of Soochow University
Qilu Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
On May 30,2018 ,Investigators intend to conduct a multicenter, randomized, double-blind, placebo-controlled study of idebenone in the treatment of early-stage Parkinson's disease with motor and non-motor symptoms which is to observe the therapeutic effect of idebenone on motor symptoms and non-motor symptoms in patients with early Parkinson's disease。
Timeline
- Start
- 2019-01-01
- Primary completion
- 2020-12-30
- Completion
- 2021-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Idebenone | Small molecule | 180 mg | Oral |
| Subject | Idebenone | Small molecule | 360 mg | Oral |